Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBW 2948 BS in COPD with Chronic Bronchitis
NCT00726479Phase 2
Key facts
- Status
- Withdrawn
- Start
- Aug 2008
- Primary completion
- Sep 2008
- Countries
- 3
- Sponsor
- Boehringer Ingelheim
- Modality
- Small Molecules
- Drugs
- BIBW 2948 BS
- Conditions
- chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
01
Overview
Phase 2, randomised, double-blind trial of BIBW 2948 BS in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB), sponsored by Boehringer Ingelheim. Planned start Aug 2008; status: withdrawn.
02
Design
- Study design
- RandomizedDouble-blind
03
Registry description
The primary objective of this study is to investigate the effect of 4-week treatment with 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS and placebo on cough and sputum as determined by the CASA-Q (Cough and Sputum Assessment Questionnaire
Beyond the preview
Go deeper on NCT00726479.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726479.